Scinai Immunotherapeutics Ltd. (SCNI)
↓ Download CSV- Sector Manufacturing
- Incorporated L3
- Fiscal year ends Dec 31
In fiscal 2025, Scinai Immunotherapeutics Ltd. reported revenue of $1.31M, up 99.2% from the prior year. The company ran a net loss, with a net margin of -633.6% and a gross margin of -202.3%.
Key ratios (FY2025)
-202.3%
Gross margin
-575.3%
Operating margin
-633.6%
Net margin
-102.5%
Return on equity
+99.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.31M | $658.0K | — | — | — | — |
| Cost of Revenue | $3.96M | $1.24M | — | — | — | — |
| Gross Profit | -$2.65M | -$580.0K | — | — | — | — |
| Operating Income | -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.86M | — |
| Net Income | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M | — |
| EPS (Diluted) | — | — | $0.00 | $0.01 | $-0.02 | — |
| Total Assets | $11.63M | $13.45M | $17.47M | $27.07M | $32.04M | — |
| Shareholders' Equity | $8.10M | $9.98M | -$4.57M | -$1.76M | $982.0K | -$15.04M |
| Cash & Equivalents | $1.66M | $1.96M | $4.87M | $14.07M | $17.37M | — |
| Operating Cash Flow | -$6.03M | -$6.33M | -$9.38M | -$7.26M | -$7.43M | — |
| Capital Expenditures | $24.0K | $12.0K | $637.0K | $836.0K | $139.0K | — |
| Shares Outstanding | 13.87B | 3.41B | 1.86B | 989.29M | 739.05M | — |